{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T13:50:39Z","timestamp":1756993839825},"reference-count":0,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T00:00:00Z","timestamp":1451865600000},"content-version":"vor","delay-in-days":16988,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[1969,7]]},"abstract":"<jats:p>A great expansion of interest has occurred in the syndrome of circulatory shock. The measurement of hemodynamic and metabolic variables in human beings and experimental animals now allows an orderly and integrated approach to the ill patient. In cardiogenic shock the minute output of the acutely iniured heart abruptly decreases with attendant fall in arterial blood pressure, tissue perfusion, and pH. Effective venous return to the right and left heart may be monitored by central venous pressure and pulmonary artery diastolic pressure. If low, infusion of volume expanders alone may be sufficient to reverse the shock syndrome. If drugs are required, a variety of catecholamines with alpha and beta stimulating properties are available, as well as inotropic agents such as digitalis and glucagon. Principles for their selection are discussed. The potential roles and hazards of alpha\u2010 and beta\u2010adrenergic blocking agents and steroids are also considered. When limits of pharmacologic resuscitation have been reached, mechanical aid and surgical assistance to the cardiovascular system are available. The latter promises to pe of greater importance in the future.<\/jats:p>","DOI":"10.1002\/cpt1969104449","type":"journal-article","created":{"date-parts":[[2016,1,5]],"date-time":"2016-01-05T01:05:08Z","timestamp":1451955908000},"page":"449-467","source":"Crossref","is-referenced-by-count":10,"title":["Cardiogenic shock: A review"],"prefix":"10.1111","volume":"10","author":[{"given":"Mark G.","family":"Perlroth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald C.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,1,4]]},"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt1969104449","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt1969104449","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt1969104449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:34:44Z","timestamp":1699364084000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt1969104449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1969,7]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1969,7]]}},"alternative-id":["10.1002\/cpt1969104449"],"URL":"https:\/\/doi.org\/10.1002\/cpt1969104449","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[1969,7]]}}}